Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10410981" target="_blank" >RIV/00216208:11110/20:10410981 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/20:00115280 RIV/00023728:_____/20:N0000068

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=B9bFzFxCZ~" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=B9bFzFxCZ~</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1080/14712598.2020.1694900" target="_blank" >10.1080/14712598.2020.1694900</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

Popis výsledku v původním jazyce

Objectives: To assess the role of short-term response to first anti-TNF in long-term prediction of disability. Methods: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression. Results: 2,274 biologicals-naive patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI &lt; 4 (77.4%) and ASDAS-CRP &lt; 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by approximate to 2.5-fold. ASDAS-CRP &lt; 2.1 predicted non-disability better than BASDAI &lt; 4 &amp; CRP &lt; 5 mg/L (p = 0.032). BASDAI &lt; 4 &amp; CRP &lt; 5 mg/L was comparable to BASDAI &lt; 4 (p = 0.941) and to BASDAI change by &gt;50% or by &gt;2 points (p = 0.902). ASDAS-CRP change &gt;1.1 and &gt;2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below euro3,000 in those reaching ASDAS-CRP &lt; 2.1. Conclusions: Low disease activity measured by ASDAS-CRP &lt;= 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.

Název v anglickém jazyce

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry

Popis výsledku anglicky

Objectives: To assess the role of short-term response to first anti-TNF in long-term prediction of disability. Methods: In nationwide registry ATTRA, we identified ankylosing spondylitis patients starting anti-TNF between 01/2003 and 12/2016. Full disability and work impairment (WI; WPAI questionnaire) were predicted via the Cox- and lagged-parameter mixed-effect regression. Results: 2,274 biologicals-naive patients newly indicated to anti-TNF were prospectively followed (6,333 patient-years; median follow-up 1.9 years). Reaching BASDAI &lt; 4 (77.4%) and ASDAS-CRP &lt; 2.1 (61.1%) after 3 months of anti-TNF both decreased the risk of future disability by approximate to 2.5-fold. ASDAS-CRP &lt; 2.1 predicted non-disability better than BASDAI &lt; 4 &amp; CRP &lt; 5 mg/L (p = 0.032). BASDAI &lt; 4 &amp; CRP &lt; 5 mg/L was comparable to BASDAI &lt; 4 (p = 0.941) and to BASDAI change by &gt;50% or by &gt;2 points (p = 0.902). ASDAS-CRP change &gt;1.1 and &gt;2.0 both failed to predict non-disability. Once on anti-TNF therapy, the strongest predictor of WI was Pain (SF36). Yearly increase in indirect costs remains below euro3,000 in those reaching ASDAS-CRP &lt; 2.1. Conclusions: Low disease activity measured by ASDAS-CRP &lt;= 2.1 should be used to measure the outcome of new anti-TNF therapy. Continuous WI could be decreased through pain management.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30226 - Rheumatology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Expert Opinion on Biological Therapy

ISSN

1471-2598

e-ISSN

—

Svazek periodika

20

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

10

Strana od-do

183-192

Kód UT WoS článku

000498457000001

EID výsledku v databázi Scopus

2-s2.0-85075441489